Improvement in impact of genital psoriasis on sexual activity with use of Taltz .- Eli Lilly.

Eli Lilly and Company announced that patients with moderate-to-severe genital psoriasis treated with Taltz (ixekizumab) reported a greater decrease in the impact of their condition on sexual activity compared to placebo after 12 weeks of treatment. Results from the Phase IIIb trial will be presented in an oral presentation at the annual meeting of the American Academy of Dermatology, taking place February 16-20, in San Diego, Calif.

At 12 weeks, patients reported the following outcomes: DLQI Item 9 0/1: 92.0 percent of patients treated with Taltz compared to 56.8 percent of patients treated with placebo (p < 0.001) reported no (0) or little (1) sexual difficulties caused by skin symptoms. SFQ Item 2 0/1: 78.4 percent of patients treated with Taltz compared to 21.4 percent of patients treated with placebo (p < 0.001) reported the frequency of sexual activity was either never (0) or rarely (1) limited by genital psoriasis. GPSIS-Avoidance 1/2: 76.7 percent of patients treated with Taltz compared to 25.7 percent of patients treated with placebo (p < 0.001) reported never (1) or rarely (2) avoiding sexual activity due to genital psoriasis. GPSIS-Impact 1/2: 85.7 percent of patients treated with Taltz compared to 52.9 percent of patients treated with placebo (p=0.062) reported worsening of genital psoriasis symptoms during or after sexual activity was very low/none at all (1) or low (2). Taltz was superior to placebo as early as week one on the limitations on frequency of sexual activity due to genital psoriasis (p < 0.05), week two for the sexual difficulties caused by skin symptoms (p < 0.001).

The most common ( greater than 4 percent) adverse events observed in patients treated with Taltz in this study were upper respiratory tract infections, injection-site reactions, headache, oropharyngeal pain and pruritus. The safety outcomes were consistent with the overall safety profile of Taltz.